Pricing Log in Create free account
Sunday 18 October 2026 Export IVF’s income statement to Excel — free account

INVO Fertility, Inc

IVF Healthcare Medical Devices

INVO Fertility, Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.8 million, up 4.74% from fiscal 2024. In the quarter to June 2026, revenue grew 16.7%, EPS grew 100.1%, free cash flow grew 35.1% and total debt fell 50.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

0.56 0.03 −5.08%
Market cap
$2.8M
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
4/9
Altman Z
−7.60
Beneish M
−1.33
Dividend safety
n/a
Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.00
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — 1 — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 2.82
Revenue 7.53
Net Income (6.95)
Free Cash Flow (4.82)
Net Debt (3.22)
Current Ratio 0.71 (below 1: weak)
Debt/Equity 0.03 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (0.02) (negative: loss-making)
P/S ratio 0.16
P/B ratio 0.07
Past 5Y EPS Growth —
This Y EPS Growth 98.05% (at or above 15%: strong)
Next Y EPS Growth 65.52% (at or above 15%: strong)
Next Y revenue growth 52.31% (at or above 10%: strong)
Next 5Y EPS Growth 93.49% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −0.3×, against a ten-year median of 19.3×; over the ten years it ranged from −0.3× in 2026 to 3,822,094,606× in 2016.
P/S against its own 10 years 6.67%
10-year low 10-year high
P/B against its own 10 years 0.48%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2019 Powerpack
2018 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 0 1 2 4
Receivables 0 0 0 0
Inventory 0 0 0 0
Other — 0 — —
1 1 3 5
2023 2024 2025 Q'26
Payables 2 3 2 2
ST’ Debt — — — —
Other 3 7 6 2
8 18 10 7

Compound Annual Growth %

10y 5y 3y
Sales 89.10% 45.83% 102.64%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 4.70% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 2 2 — — —
’25 2 2 2 2 7
’24 2 2 1 2 7
’23 0 0 1 1 3
’22 0 0 0 0 1
’21 1 0 0 3 4
’20 0 0 0 0 1
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) (1) — — —
’25 (4) (2) (2) 0 (7)
’24 0 (1) (1) (1) (3)
’23 (1) (2) (1) (1) (5)
’22 (2) (2) (2) (1) (7)
’21 (2) (1) (2) (2) (6)
’20 (1) (1) (1) (2) (5)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) (1) — — —
’25 (4) (2) (2) 0 (7)
’24 0 (1) (1) (1) (3)
’23 (1) (2) (1) (1) (5)
’22 (2) (2) (2) (1) (7)
’21 (2) (1) (2) (1) (6)
’20 (1) (1) (1) (2) (5)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (3.38) 0.35 — — —
’25 (1.50k) (532.00) (30.80) 3.67k (214.64)
’24 (908.06) (893.25) (605.10) (1.08k) (3.62k)
’23 (5.76k) (4.41k) (1.01k) 3.24k (7.39k)
’22 (6.63k) (6.63k) (6.05k) (6.63k) (25.93k)
’21 (7.20k) (4.90k) (6.92k) 959.86 (18.15k)
’20 (8.46k) (7.84k) (10.37k) (17.29k) (43.80k)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 184,314.81 111,510.46 73,725.92 156,667.59 80,639.96 76,896.00 9,475.20 720.00 908.64 3.55

Analyst estimates 2026–2028

Powerpack
High 663,533.31 368,629.63 709,612.00 479,218.50 440,723.06 354,240.00 110,448.00 23,616.00 5,040.00 1,497.60
People
People Employees 3 1 2 5 10 12 14 30 32 42
Revenue/emp, $m 0.02 0.28 0.25 0.30 0.10 0.35 0.06 0.10 0.20 0.16
Income, $m
Income, $m Revenue 0 0 0 1 1 4 1 3 7 7
Gross margin, % 70.33 81.60 81.72 90.97 91.44 96.51 (3.48) 35.96 44.00 36.96
EBT (2) (1) (3) (2) (8) (7) (11) (8) (8) (5)
EBT margin, % (4,173.48) (248.92) (622.19) (146.41) (804.71) (159.86) (1,324.45) (265.07) (116.35) (80.19)
Net income (2) (1) (3) (2) (8) (7) (11) (8) (9) (23)
Depreciation 0 0 0 0 3 1 0 1 2 2
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 7,401.00 5,186.50 10,400.25 2,055.50 3,020.60 2,177.33 58.47
Earnings (0.02) 0.00 (0.02) (9,220.61) (43,797.89) (18,153.07) (25,932.96) (7,390.90) (3,623.16) (214.64)
Cash flow 0.00 0.00 0.00 6,852.50 (23,875.50) (15,074.75) (16,508.25) (4,755.10) (991.47) (59.95)
Capex 0.00 0.00 0.00 (573.50) (445.00) (1,136.50) (31.75) (444.70) (36.03) (0.37)
Free cash flow 0.00 0.00 0.00 6,279.00 (24,320.50) (16,211.25) (16,540.00) (5,199.80) (1,027.50) (60.32)
Book value (0.03) (0.04) (0.02) (18,568.00) 28,715.50 18,276.75 (2,444.00) 892.60 4,194.80 61.75
Shares, m 139 141 147 0 0 0 0 0 0 0
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 883,505,236.93 69,243,011.43 115,368,949.17 26.92 16.71 9.22 6.15 0.61 0.54 0.06
P/B 0.00 0.00 0.00 0.00 3.02 5.25 0.00 0.00 0.00 0.09
EV/Sales 883,505,236.72 69,243,011.84 115,368,949.44 26.34 7.55 8.37 9.28 1.64 1.41 (0.11)
EV/FCF (138,567,662.94) (107,741,057.03) (87,330,584.54) 29.86 (1.61) (5.34) (1.15) (0.95) (2.98) 0.11
Cash, $m
Cash, $m Operating cash flow 0 0 (1) 1 (5) (6) (7) (5) (3) (7)
Capex 0 — 0 0 0 0 0 0 0 0
Free cash flow 0 0 (1) 1 (5) (6) (7) (5) (3) (7)
Balance, $m
Balance, $m Working capital (5) (5) (3) 0 8 5 (3) (7) (17) (8)
Total debt 0 0 0 0 1 2 2 1 1 1
Net debt 0 0 0 (1) (10) (4) 2 1 1 (1)
Shareholders’ equity (5) (5) (3) (4) 6 7 (1) 1 13 7
Returns, %
Returns, % ROA (490.60) (254.14) (589.46) (168.49) (131.01) (62.16) (153.67) (72.33) (29.45) (75.81)
ROIC 0.00 0.00 0.00 0.00 0.00 (92.43) (1,102.70) (220.95) (31.64) (76.78)
ROE 50.73 14.61 79.73 67.34 (822.60) (101.96) (343.99) 264.08 83.06 387.43
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

INVO Fertility, Inc vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ICCM IceCure Medical Ltd. $3.6M — (loss-making) — (loss-making) −0.69% (below 0%: shrinking) n/m +3.88% (above 0%: growing) 32.38% (466.19%) Compare
BJDX Bluejay Diagnostics, Inc. $3.5M 0.9× — (loss-making) — n/m +20.05% (above 0%: growing) 0.00% 0.00% Compare
IVF INVO Fertility, Inc $2.8M 0.0× — (loss-making) +16.73% (above 0%: growing) n/m +35.07% (above 0%: growing) 35.06% (59.28%)
ADGM Adagio Medical Holdings, Inc. $2.8M — (loss-making) — −33.50% (below 0%: shrinking) n/m −12.86% (below 0%: shrinking) 0.00% 0.00% Compare
NXL Nexalin Technology, Inc. $2.6M — (loss-making) — (loss-making) −82.72% (below 0%: shrinking) n/m −97.23% (below 0%: shrinking) 72.95% (18,420.49%) Compare
BIOLQ Biolase, Inc. $2.3M — (loss-making) — (loss-making) −0.65% (below 0%: shrinking) n/m −60.22% (below 0%: shrinking) 40.39% (6.41%) Compare
XAIR Beyond Air, Inc. $2.2M — (loss-making) — (loss-making) +0.45% (above 0%: growing) n/m −9.10% (below 0%: shrinking) 12.73% (373.98%) Compare
NUVOQ Holdco Nuvo Group D.G Ltd. $2.1M — (loss-making) — — n/m −1.05% (below 0%: shrinking) 0.00% 0.00% Compare
VJET Flyte Aviation, Inc. $2.1M — (loss-making) — (loss-making) +380.66% (above 0%: growing) n/m −26.70% (below 0%: shrinking) 9.62% (388.13%) Compare
Median of peers $2.5M — — −0.67% — −10.98% 11.17% (190.19%)

All 149 Medical Devices stocks →

INVO Fertility, Inc (IVF) key facts

  • Strength: INVO Fertility, Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.8 million, up 4.74% from fiscal 2024.
  • INVO Fertility, Inc (IVF) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, IVF traded at $0.56, a market capitalization of $2.8 million.
  • Return on equity was 387.4% and debt-to-equity 0.03.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −7.60 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

INVO Fertility, Inc (IVF) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/IVF · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com